Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Eupraxia Pharmaceuticals Inc. (T:EPRX)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for EPRX within the last 6 months
Loading...
See all filings within the past 6 months

Company News

May 05, 2022 17:00 ET
Eupraxia Pharmaceuticals Reports First Quarter 2022 Financial Results
VICTORIA, BC, May 5, 2022 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the first quarter ended March 31, 2022. All amounts are expressed in Canadian dollars unless otherwise indicated.
Read full article
Apr 20, 2022 09:39 ET
IIROC Trade Resumption - EPRX.WT.A
TORONTO, April 20, 2022 /CNW/ - Trading resumes in:
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
13.71
6.01
Price to Book - most recent quarter
0.94
2.07
1.77
Price to Cash Flow per share - TTM
--
8.61
9.50
Price to Free Cash Flow per share - TTM
--
45.73
22.85
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Apr 30, 20226,775-145,585
Apr 15, 2022152,360147,150
Mar 31, 20225,210-3,039
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its lead product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). EP-104IAR contains a solid core of the active ingredient Fluticasone Propionate (FP) with an outer layer of the biocompatible polymer, PVA. In addition to EP-104IAR, the Company is also developing a pipeline of earlier-stage long-acting formulations. It develops pipeline candidates for a range of indications, such as post-surgical pain (EP-105), and post-surgical site infections (EP-201). The Company has completed a phase I, double-blind, placebo-controlled clinical study at three sites in Canada.

See business summary

 

Twitter

Search (past week) for $EPRX.CA

  • No tweets found